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OBJECTIVES: Economic evaluation requires reliable esti-
mation techniques for hospital costing in multinational
trials. We have developed methods to assign costs to all
hospitalizations by multiplying country-speciﬁc cost 
estimates for a “base” diagnosis by a relative DRG weight
(U.S. DRG weight for the diagnosis in question/DRG
weight for the “base” diagnosis). Our objective was to
assess the validity of calculating country-speciﬁc cost 
estimates computed with U.S.-based DRG weights.
METHODS: Unit costs collected alongside Val-HeFT, a
multinational trial in heart failure, were used to compare
cost estimates provided by local economists with esti-
mates computed using U.S.-based DRG weights. Unit 
cost estimates for 8 diagnoses from 14 countries were
evaluated. We calculated the correlation between the cost
estimates and performed regression analysis to examine
the relationship between them.
RESULTS: When hospitalization for heart failure was
used as the “base” diagnosis, DRG-based cost estimates
were within 35% of the survey estimates for 86% of the
countries for unstable angina, 82% for acute MI, stroke,
and colon cancer. Costs were less well predicted for pul-
monary embolism, coronary stenting, PTCA, and heart
transplant, where only 61.5%, 54.5%, 33.3% and
30.0% of predicted costs were within 35% of survey 
estimates. The DRG-based estimates appeared to over-
estimate costs for procedure-based diagnoses as the costs
were overestimated by 40.3% for stenting, 34.9% for
PTCA, and 77.8% for heart transplant. The Pearson cor-
relation coefﬁcient between the two sets of estimates was
0.682. When excluding heart failure, the regression of
DRG-derived costs on survey-derived costs indicated that
the DRG-based methodology predicted cost estimates
fairly well (adj-R2 = 0.44) (adj-R2 = 0.571 when adjust-
ing for country).
CONCLUSIONS: Estimation of hospital costs based on
U.S. DRG weights appears to be a reasonable solution 
to costing problems in the multinational trial setting.
However, care is required in applying this technique in
studies with high frequencies of surgical procedures.
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Pharmacoeconomic analysis aims to identify and measure
all costs and all outcomes associated with providing a
pharmaceutical product or service. In order to accomplish
this several economic study techniques have been used 
in the pharmacoeconomic literature in various disease
areas.
OBJECTIVES: To determine if there is a relationship
between the type of study (e.g. cost-effectiveness (CEA),
cost-beneﬁt (CBA), cost-minimisation (CMA), cost-utility
analysis (CUA)) used in a pharmacoeconomic analysis
and the disease area being investigated.
METHODS: Five disease areas, as categorised by the
British National Formulary 1 were investigated. A broad
literature search, using MESH terms, was performed
using Medline (PubMed) and abstracts that included full
and partial pharmacoeconomic analyses, from 1966 until
the present day, were considered for review.
RESULTS: 119 abstracts were. No cost-beneﬁt analyses
were found and the most commonly used full economic
techniques were cost-effectiveness and cost-utility analy-
sis; whilst cost analysis was the most commonly used
partial analytic technique. CEA was the preponderant
technique employed in the cardiovascular, respiratory 
and central nervous system disease areas, with contri-
butions of 50% (24/48), 43.48% (10/28) and 45.45%
(5/11) respectively. CUA was preponderant in the
endocrinal disease area, 30.77% (4/13), whilst CEA and
CUA were equally employed in the area of gastrointesti-
nal disease, 33.33% (8/24) and 25.00% (6/24) respec-
tively. Cost-analysis did not dominate any disease area,
and was not found to be preponderant in any speciﬁc
disease area.
CONCLUSION: Although this initial review found that
CEA was the preponderant technique employed in the
cardiovascular, respiratory and central nervous system
disease areas and CUA in the endocrinal disease area, the
relatively small number of papers reviewed cannot allow
one to draw conclusions regarding deﬁnite relation-
ships between disease areas and the type of studies used.
Further analysis of the pharmacoeconomic literature is
required to investigate possible relationships further and
highlight these where they occur.
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OBJECTIVES: To explore the use of sub-group analysis
in economic evaluation and to compare the relevance 
of such analyses to the standard recommendations for
approaching sub-group analysis in clinical studies.
METHODS: The standard pitfalls associated with ad hoc
sub group analyses in clinical evaluation are well known,
and such analyses are generally discouraged. However, in
economics, small differences in effect between sub-groups
can lead to important differences in cost-effectiveness 
for those groups. This suggests that sub-group analysis is
of critical importance for economic evaluation and the
policy decision that such evaluations seek to inform.
However, we must remain mindful of the potential pit-
falls in terms of inappropriate inference, especially when
